Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 62% of modeled bridge. Strengths: Commercial Payer %, Bed Count. Risks: Occupancy Rate, Net-to-Gross Ratio. Risk-adjusted uplift: $1.0M (vs $1.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $599K | $599K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $576K | $16K | $593K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $92K | $272K | $364K | $1.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $19K | $19K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 77.8% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $150K | $299K | $449K | $599K | $599K | $599K | $599K |
| Denial Rate Reduction | $0 | $148K | $296K | $444K | $593K | $593K | $593K | $593K |
| A/R Days Reduction | $0 | $121K | $243K | $364K | $364K | $364K | $364K | $364K |
| Clean Claim Rate | $0 | $10K | $19K | $19K | $19K | $19K | $19K | $19K |
| Cumulative | $0 | $429K | $858K | $1.3M | $1.6M | $1.6M | $1.6M | $1.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 141% / 80.9x | 146% / 90.2x | 151% / 99.5x | 153% / 104.2x | 156% / 108.9x |
| 9.0x | 135% / 71.5x | 140% / 79.8x | 145% / 88.1x | 147% / 92.3x | 149% / 96.4x |
| 10.0x | 130% / 64.0x | 135% / 71.5x | 140% / 79.0x | 142% / 82.7x | 144% / 86.5x |
| 11.0x | 125% / 57.9x | 130% / 64.7x | 135% / 71.5x | 137% / 74.9x | 139% / 78.3x |
| 12.0x | 121% / 52.8x | 126% / 59.0x | 131% / 65.3x | 133% / 68.4x | 135% / 71.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 89% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 0.7x, adding 7.7 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $152K | — | $152K | 0.5% |
| Year 1 | $157K | +$1.0M | $1.2M | 4.0% |
| Year 2 | $162K | +$1.6M | $1.7M | 5.8% |
| Year 3 | $166K | +$1.6M | $1.7M | 5.8% |
| Year 4 | $171K | +$1.6M | $1.7M | 5.8% |
| Year 5 | $176K | +$1.6M | $1.8M | 5.9% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $299K | $449K | $599K | $718K |
| Denial Rate Reductio | $296K | $444K | $593K | $711K |
| A/R Days Reduction | $182K | $273K | $364K | $437K |
| Clean Claim Rate | $10K | $14K | $19K | $23K |
| Total | $787K | $1.2M | $1.6M | $1.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 66 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 0.5% | -12.9% | -4.8% | 0.8% | P71 |
| Net-to-Gross | 64.1% | 61.2% | 70.3% | 77.8% | P33 |
| Occupancy | 20.6% | 11.6% | 18.2% | 25.7% | P59 |
| Rev/Bed | $1.2M | $763K | $1.3M | $1.9M | P42 |
| Exp/Bed | $1.2M | $789K | $1.4M | $2.1M | P39 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.